Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

Fig. 1

The duration and prescribing pattern of omalizumab: a The duration of omalizumab treatment: A total of 282 patients with moderate to severe asthma receiving omalizumab were enrolled. The mean duration of omalizumab treatment was 243.8 ± 265.4 days. b The prescribing pattern: Overall, 44 % of the patients received omalizumab therapy for less than 4 months with a mean duration of 70.1 ± 34.8 days, and 56 % of the patients received omalizumab for more that 4 months, including 15 % (4–6 months), 12 % (6–8 months), 9 % (8–12 months), and 21 % (over 12 months)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us